医学
抗血栓
经皮冠状动脉介入治疗
心肌梗塞
心脏病学
内科学
指南
纤溶剂
重症监护医学
病理
作者
Felix Voll,Constantin Kuna,Gjin Ndrepepa,Adnan Kastrati,Salvatore Cassese
标识
DOI:10.1080/14779072.2021.1902807
摘要
Despite a timely mechanical reperfusion with primary percutaneous coronary intervention (pPCI) patients presenting with ST-elevation myocardial infarction (STEMI) display an increased risk of adverse cardiovascular events. Several studies have demonstrated that guideline-directed antithrombotic therapy is effective to reduce this risk. However, there is still much to be accomplished to improve antithrombotic therapies in this clinical setting.This paper reviews current data on antithrombotic therapy in STEMI patients undergoing pPCI.Antithrombotic therapy for STEMI patients undergoing pPCI should take into account the variability of thrombotic and bleeding risk in the short and long term. Patients with STEMI profit from the administration of early onset antiplatelet agents and anticoagulation to achieve sufficient and predictable antithrombotic effect at the time of pPCI. Thereafter, antithrombotic therapies should be tailored to individual risk of recurrence over the long term, to avoid excess bleeding, while ensuring adequate secondary ischemic prevention.
科研通智能强力驱动
Strongly Powered by AbleSci AI